Heron Therapeutics, Inc. reiterated net product sales guidance for the full year 2023. The company is reiterating full-year 2023 net product sales guidance for the oncology care franchise of $99 million to $103 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.41 USD | -0.87% | -0.87% | +100.59% |
May. 15 | Transcript : Heron Therapeutics, Inc. - Analyst/Investor Day | |
May. 07 | Transcript : Heron Therapeutics, Inc., Q1 2024 Earnings Call, May 07, 2024 |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+100.59% | 514M | |
+54.05% | 58.71B | |
-2.02% | 41.31B | |
+37.57% | 39.2B | |
-10.22% | 27.4B | |
+13.42% | 26.55B | |
-21.60% | 18.98B | |
+2.89% | 12.51B | |
+22.40% | 11.94B | |
+27.49% | 12.08B |
- Stock Market
- Equities
- HRTX Stock
- News Heron Therapeutics, Inc.
- Heron Therapeutics, Inc. Reiterates Net Product Sales Guidance for the Full Year 2023